Genetic Function
FDA Approves Rybrevant for Third NSCLC Indication This Year
Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment
Novo Nordisk and Korro Bio Collaborate on $530M RNA Editing Deal for Cardiometabolic Diseases
Novo Nordisk, Korro Bio, RNA editing, cardiometabolic diseases, genetic medicines, pharmaceutical partnerships
Relay Therapeutics Advances Towards Pivotal Trial with Promising Breast Cancer Data, Setting Stage for Competition with AstraZeneca’s Truqap
Relay Therapeutics, RLY-2608, Breast Cancer, PI3Kα Mutations, Pivotal Trial, AstraZeneca, Truqap
Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis
FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications
FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression
FDA to Reassess Checkpoint Inhibitors for Stomach Cancer Based on PD-L1 Expression
FDA, checkpoint inhibitors, stomach cancer, PD-L1 expression, Oncologic Drugs Advisory Committee
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments